Trial Profile
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Topotecan (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 28 May 2021 Results published in the British Journal of Cancer.
- 05 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2022.